Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program by Kim, Catherine et al.
Sex Steroid Levels and Response to Weight Loss
Interventions among Postmenopausal Women in the
Diabetes Prevention Program
Catherine Kim1, Elizabeth Barrett-Connor2, John F. Randolph3, Shengchun Kong4, Bin Nan4, Kieren J. Mather5,
Sherita H. Golden6 and the Diabetes Prevention Program Research Group
Objectives: To examine whether estrogen use potentiates weight loss interventions via sex steroid levels
and whether endogenous sex steroid levels predict response to weight loss interventions among women
not using estrogen.
Methods: The Diabetes Prevention Program randomized overweight or obese dysglycemic participants
to lifestyle change with the goals of weight reduction of >7% of initial weight and 150 minutes per week
of exercise, metformin, or placebo. In this secondary analysis, we examined sex steroid levels and reduc-
tions in weight and waist circumference (WC) among postmenopausal women using (n5 324) and not
using (n5 382) oral estrogen.
Results: Estrogen users and nonusers randomized to lifestyle change and metformin both lost significant
amounts of weight compared to placebo. Reductions in weight and WC over 1 year associated with ran-
domization arm were not associated with baseline sex steroid levels among estrogen users or nonusers.
Conclusions: Among estrogen users, baseline sex steroids were not associated with reductions in weight
or WC, suggesting that exogenous estrogen does not potentiate weight loss by altering sex steroids.
Among nonestrogen users, baseline sex steroids were not associated with reductions in weight or WC.
Obesity (2014) 22, 882–887. doi:10.1002/oby.20527
Introduction
Randomized trials of estrogen therapy suggest that it has neutral (1)
or favorable effects (2) on weight loss in overweight or obese post-
menopausal women. Reports on whether estrogen therapy can potenti-
ate or interfere with weight loss interventions are few, and contradic-
tory. In one study, postmenopausal women randomized to both an
exercise intervention and estrogen use had the greatest reductions in
fat mass, followed by women who were randomized to exercise
alone; to estrogen alone; and finally no-intervention controls(3). Such
reductions in fat were assumed to occur through changes in sex ste-
roid levels, specifically increases in estradiol (E2) and decreases in
androgen levels, although these were not measured in this study. In
contrast, two small trials of estrogen therapy reported that women
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randomized to oral estrogen had increases in fat mass and reductions
in lean body mass compared to women randomized to transdermal
estrogen, suggesting that altered serum E2 levels were not a key
mechanism of weight loss among estrogen users (4,5). Another trial
of estrogen therapy reported that women randomized to oral estrogen
had reductions in lean body mass but no changes in fat mass com-
pared to controls (6). Finally, another study that randomized women
to lifestyle change (7) found that reductions in weight and waist cir-
cumference (WC) were similar in interventions versus controls
regardless of estrogen use, suggesting that neither estrogen use nor E2
levels modified response to weight loss interventions. Of note, sex
steroid levels were not reported in these studies.
The Diabetes Prevention Program (DPP) randomized nondiabetic,
overweight or obese, glucose-intolerant participants to a program of
intensive lifestyle (ILS) modification, metformin, or placebo (8). Par-
ticipants randomized to ILS and metformin had maximal weight loss
and reductions in glucose at 1 year after randomization (8). We have
previously reported that postmenopausal women who were over-
weight and glucose-intolerant had significant reductions in weight and
WC when randomized to ILS change or metformin compared to pla-
cebo (9). Changes were observed among women who used oral estro-
gen at baseline and 1-year follow-up as well as among women who
did not use any exogenous estrogen at either time (10).
The DPP data provide the opportunity to examine the pattern of
weight loss and WC in estrogen users and nonestrogen users, and
whether baseline serum sex steroid levels were associated with the
degree of weight loss and reductions in WC among women random-
ized to interventions. We hypothesized that greater E2 levels and
decreased testosterone and dehydroepiandrosterone (DHEA) levels
at baseline would be associated with greater reductions in weight
and WC among women randomized to ILS or metformin compared
to placebo.
Methods
Characteristics of DPP participants have been reported (8). Briefly,
the DPP inclusion criteria included age >25 years, fasting plasma
glucose (FPG) of 95-125 mg/dl and 2-hour plasma glucose of 140–
200 mg/dl following a 75-gram glucose load, and body mass index
(BMI) 24 kg/m2 (22 kg/m2 for Asian Americans). Written
informed consent was obtained from all participants before screen-
ing, consistent with the guidelines of each participating center’s
institutional review board.
Eligible participants were randomly assigned to one of three inter-
ventions: 850 mg metformin twice daily, placebo twice daily, or
ILS. The goals of ILS were to achieve and maintain a weight reduc-
tion of at least 7% of initial body weight through consumption of a
low-calorie, low-fat diet, plus moderate physical activity for at least
150 minutes per week(8). Weight and WC were measured semiann-
ually, and participants had an annual oral glucose tolerance test and
semiannual FPG test. At the time of randomization, all women com-
pleted a questionnaire about their menses, gynecological history
including surgeries, and about estrogen use (contraceptive and post-
menopausal therapy). Medication use was reassessed every 6
months.
Women were classified as postmenopausal if they met any of the
following criteria: bilateral oophorectomy, lack of menses for at
least 1 year while retaining uterus and at least one ovary, cessation
of menses prior to hysterectomy, cessation of menses within the past
year and age >55 years, and cessation of menses with hysterectomy
and age >55 years. For this report, we included women who con-
sented for participation in ancillary studies, were postmenopausal at
randomization, had an available stored serum sample for sex steroid
measurement, and could be categorized as oral estrogen users both
at randomization as well as at 1 year follow-up (n5 324), or as non-
users both at randomization and 1 year follow-up (n5 382). Women
who used injection, implant, transdermal, or transvaginal estrogen
were excluded, as were women who used any estrogen at baseline
but not at follow-up and vice-versa. We have previously reported
the characteristics of estrogen users (10); of the 324 women who
reported using oral estrogen at baseline and at follow-up, 266
women were estrogen-only users at baseline and 58 women used
estrogen-progestin; at year 1 follow-up, 258 women were estrogen-
only users and 66 women used estrogen-progestin, and the most
common estrogen used was conjugated equine estrogen.
For diabetes diagnosis, an oral glucose tolerance test was performed
between 7 a.m. and 11 a.m. after an overnight fast. Venous blood
was sampled before and 2 hours after a 75 gram oral glucose load
(Trutol 75; Custom Laboratories, Baltimore, MD). Plasma glucose
was measured fasting and at 2 hours; plasma insulin was measured
fasting. Insulin sensitivity was assessed using inverse fasting insulin
levels (1/fasting insulin). All analytical measurements were per-
formed at a central Biochemistry Laboratory (University of Wash-
ington, Seattle, WA). Plasma glucose was measured on a chemistry
autoanalyzer by the glucokinase method. Insulin measurements were
performed by a radioimmunoassay method using an anti–guinea pig
antibody that measures total immunoreactive insulin. The insulin
assay is a 48-h polyethylene glycol–accelerated method with coeffi-
cients of variation (CVs) of 4.5% for high-concentration quality con-
trol samples and 6.9% for low-concentration quality control samples.
The CV for masked split duplicates in this assay was <8.5%.
We have previously reported sex hormone measurement procedures
(9). Briefly, SHBG, follicle stimulating hormone (FSH), total E2,
total T, and DHEA were measured on heparinized plasma collected
at baseline and year 1. SHBG was measured at Endoceutics (Quebec
City, Canada) using ELISA (Bioline) with interassay coefficients of
variation of 7.8 and 5.0 at 18.2 and 63.1 nmol/l, respectively. FSH
was measured at Endoceutics using ELISA (Bioline) with interassay
coefficients of variation of 3.6 and 4.4 at 27.1 and 72.9 mIU/ml,
respectively. E2, T, and DHEA were analyzed using gas chromatog-
raphy/mass spectrometry at Endoceutics. The limits of detection
were 3.0 pg/ml for total E2; 8.0 ng/dl for total T, and 0.30 ng/ml for
DHEA. Interassay coefficients of variation for E2 were 17.5% at 4.7
pg/ml, for T were 13.0% at 14 ng/dl, and for DHEA were 24.0% at
0.77 ng/ml. The ratio of T:E2 was also examined as a potential indi-
cator of aromatase activity, and bioavailable T and E2 were calcu-
lated according to the method described by Sodergard and col-
leagues (courtesy of Frank Stanczyk, University of Southern
California) taking the concentrations of total T, total E2, and SHBG
into account and assuming a fixed albumin concentration of 4.0 g/dl
(11).
Statistical analysis
In the first stage of analysis, women who did not use any estrogen
at baseline or follow-up and women who used oral estrogen at both
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baseline and follow-up were examined separately. For each popula-
tion, baseline characteristics were described using percentages for
categorical variables and means (SD) for quantitative variables. For
variables where the distribution was skewed, log-transformed values
and median values were used; Table 1 shows medians and interquar-
tile ranges for baseline sex steroid measures and SHBG. In order to
assess the association between baseline sex steroid and SHBG level
and change in weight, we first used t-tests or Wilcoxon rank-sum
tests to compare levels of change in weight between randomization
arms. Change in weight was calculated as year 1 weight—baseline
weight. Next, we examined the association between baseline sex ste-
roid level and these weight changes. Models which used natural
scale and log-transformed sex hormones were similar, and therefore
for ease of interpretation and to enable comparisons across sex ste-
roids, b-coefficients were standardized using the standard deviation
of each natural scale sex hormone. Because of differences in base-
line FSH by randomization arm, as well as previously reported
effects of menopausal stage upon sex steroid-adipose tissue relation-
ships (12), baseline FSH levels were also examined as a covariate.
A series of linear regression models additionally adjusted for base-
line weight, as well as age, race/ethnicity, and baseline levels of
FSH. In order to determine whether the association between sex ste-
roid and SHBG levels and weight changes varied by randomization
arm, an interaction term between sex steroid level and randomiza-
tion arm was also evaluated. Additional models stratified by ran-
domization arm. Similar models were created for evaluation of
changes in WC. In sensitivity analyses, we also evaluated models
that adjusted for fasting insulin, but this did not change the signifi-
cance of any associations, so only the models adjusting for baseline
weight or WC, age, race/ethnicity, and FSH are shown. Next, we
compared the baseline characteristics of estrogen users and nonusers
using similar procedures as those described above. We created mul-
tivariable models that introduced an interaction term between exoge-
nous estrogen use and baseline sex steroid and SHBG level, in order
to determine whether use of estrogen modified the association
between baseline sex hormone measures and changes in anthropo-
metric measures; comparisons were made stratified by randomiza-
tion arm. The SAS analysis system was used for all analyses (SAS
Institute, Cary, NC).
Results
Baseline characteristics of postmenopausal women by estrogen use
are shown in Table 1. Similar proportions of women were
TABLE 1 Characteristics of postmenopausal women by oral ET use
Nonusers Estrogen users P-value
n5382 n5 324
Randomization arm (%)
Intensive lifestyle change 35 33 0.26
Metformin 32 38
Placebo 33 29
Age (years) 58.7 (9.0) 56.5 (7.6) <0.01
Race/ethnicity (%) <0.01
Caucasian 53 66
African-American 28 16
Hispanic 16 13
Asian 3 4
Type of menopause (%) <0.01
Bilateral oophorectomy 20 42
Natural menopause 67 39
Age >55 years and hysterectomy 14 19
Years since final menstrual period 15 (10) 14 (9) 0.34
Baseline weight (kg) 91.0 (19.7) 87.6 (17.8) 0.04
Baseline waist circumference (cm) 104 (14) 101 (14) <0.01
Baseline BMI (kg/m2) 34.6 (6.8) 33.3 (6.5) 0.01
Baseline fasting insulin levels (IU/l) 26.4 (16.0) 23.4 (12.0) <0.01
Baseline fasting plasma glucose (mg/dl) 107 (8) 104 (7) <0.01
Baseline 2-hour glucose (mg/dl) 164 (17) 166 (18) 0.16
Baseline follicle stimulating hormone (IU/l) 55.3 (26.6) 34.8 (22.5) <0.01
Baseline sex hormone binding globulin (nmol/l) 33.2 (18.3) 85.3 (77.0) <0.01
Baseline total estradiol (pg/ml) 8.5 (8.0) 17.6 (14.8) <0.01
Baseline total testosterone (pg/ml) 14.0 (13.0) 15.0 (11.0) 0.44
Baseline total dehydroepiandrosterone (ng/ml) 1.6 (1.3) 1.3 (1.2) 0.01
Baseline total testosterone:estradiol 0.023 (0.04) 0.018 (0.07) <0.01
Means (SD) or percentages shown; medians (interquartile ranges or IQR) shown for sex hormones.
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randomized to ILS, metformin, or placebo among estrogen users and
nonusers. Reflecting DPP recruitment criteria, all women were over-
weight or obese at baseline and had elevated glucose levels. Women
who did not use estrogen were slightly older and more often non-
white than estrogen users. Among nonusers, the most common cause
of menopause was natural or nonsurgical cessation of menses,
whereas among estrogen users, the most common cause of meno-
pause was oophorectomy. Nonusers weighed more and had greater
WCs and higher BMIs than estrogen users. Nonusers had higher lev-
els of fasting insulin, FPG, and FSH but lower levels of SHBG and
E2 than estrogen users. No differences in T and DHEA between
estrogen users and nonusers were observed. Among nonusers,
women had similar characteristics by study arm, with the exception
that women randomized to metformin had slightly lower FSH levels
than women randomized to placebo (51.5 IU/l vs. 59.3 IU/l,
P< 0.05). Among estrogen users, women had similar characteristics
by study arm, with the exception that there were slightly more
African-American women in the metformin arm than the placebo
arm (9% vs. 5%, P< 0.05).
Among women not using estrogen at baseline or follow-up, women
randomized to ILS, metformin, and placebo lost 6.5, 3.2, and 0.95
kg of weight, respectively, and reduced WC by 6.5, 3.0, and 1.3 cm,
respectively (P< 0.05 for comparisons of each intervention vs. pla-
cebo). Among estrogen users, women randomized to ILS, metfor-
min, and placebo lost 7.0, 2.8, and 0.28 kg of weight, respectively,
and 6.0, 2.1, and 0.4 cm of WC, respectively (P< 0.05 for compari-
sons between interventions vs. placebo).
Table 2 shows the association of baseline sex steroid levels with
changes in weight and WC among women who did not use estro-
gen at baseline or 1-year follow-up. Baseline levels of SHBG and
sex steroids (E2, T, DHEA) were not significantly associated with
reductions in weight or WC. Interactions between randomization
arm and baseline sex hormone levels were not significant, indi-
cating that the strength of associations did not vary by random-
ization arm. Table 2 also shows the association between baseline
sex steroid levels with changes in weight and WC among women
who used oral estrogen at baseline and at follow-up. In
TABLE 2 Associations between baseline sex steroid and sex hormone binding globulin levels with change in weight (D weight)
and change in WC (DWC) among women who did not use estrogen and estrogen users
Among women who did
not use estrogen
Among women who used
oral estrogen
b-coefficient (95% CI) b-coefficient (95% CI)
Sex hormone binding globulin (nmol/l)
D weight 0.16 (20.66, 0.98) 20.20 (21.25, 0.86)
P5 0.70 P5 0.72
D waist circumference 0.05 (20.85, 0.94) 0.70 (20.62, 2.02)
P5 0.92 P5 0.30
Total estradiol (pg/ml)
D weight 21.3 (22.93, 0.33) 0.11 (21.14, 1.35)
P5 0.12 P5 0.86
D waist circumference 20.52 (22.28, 1.24) 20.22 (21.77, 1.34)
P5 0.56 P5 0.78
Total testosterone (pg/ml)
D weight 20.037 (20.99, 0.92) 23.5 (25.14, 21.83)
P5 0.94 P< 0.01a
D waist circumference 0.049 (21.00, 1.10) 24.8 (26.88, 22.74)
P5 0.93 P< 0.01a
Dehydroepiandrosterone (ng/ml)
D weight 0.49 (20.60, 1.59) 20.86 (21.89, 0.16)
P5 0.38 P5 0.10
D waist circumference 20.09 (21.37, 1.17) 21.3 (22.54, 0.02)
P5 0.88 P5 0.054
Total testosterone:total estradiol
D weight 20.31 (21.51, 0.89) 21.5 (22.15, 20.90)
P5 0.61 P< 0.01a
D waist circumference 20.29 (21.58, 0.99) 22.0 (22.78, 21.20)
P5 0.65 P< 0.01a
Associations adjusted for randomization arm, age, race/ethnicity, baseline follicle stimulating hormone, and baseline anthropometric measure.
aP< 0.05 for interaction with randomization arm; association significant among women randomized to placebo but not among women randomized to lifestyle change or
metformin.
Standardized b-coefficients and 95% confidence intervals (CIs) shown; a negative b-coefficient indicates that a greater baseline hormone level is associated with greater
declines in weight or WC. Bold type indicates a statistically significant association.
Original Article Obesity
EPIDEMIOLOGY/GENETICS
www.obesityjournal.org Obesity | VOLUME 22 | NUMBER 3 | MARCH 2014 885
unadjusted models, baseline levels of E2 were associated with
greater reductions in weight and WC at 1 year after adjustment for
baseline anthropometry, specifically among women randomized to
metformin (results not shown). However, these associations did not
persist after further adjustment for other covariates (Table 2). In par-
ticular, adjustment for race/ethnicity reduced the significance of
associations between E2 and weight changes and adjustment for FSH
reduced significance between E2 and WC changes. Models examin-
ing bioavailable E2 yielded similar results (not shown).
Among oral estrogen users, greater baseline levels of T were associ-
ated with greater reductions in weight and WC (Table 2). The inter-
actions between baseline levels of T and randomization to placebo
versus interventions were significant. In the placebo arm, the associ-
ation between baseline T and weight changes (P5 0.02) and WC
changes (P< 0.01) was significant, but the associations between
baseline T and anthropometric changes were not significant among
women randomized ILS or metformin. Measures incorporating T,
that is, the ratio of T: E2 showed a similar pattern of associations,
as did measures of bioavailable T (results not shown). In unadjusted
models, lower baseline levels of DHEA were associated with greater
reductions in weight, specifically among women randomized to life-
style change. However, these associations did not persist after fur-
ther adjustment for other covariates (Table 2). In particular, adjust-
ment for race/ethnicity reduced the significance of associations
between DHEA and anthropometric changes. Baseline levels of
SHBG were not associated with changes in weight or WC.
When we examined whether the strength of the associations between
baseline sex hormones varied by exogenous estrogen use, we found
that interactions between exogenous estrogen and baseline sex hor-
mone levels were not significant, suggesting that the relationship
between sex hormones and anthropometric changes was not signifi-
cant regardless of exogenous estrogen use. The exception was the
interaction between estrogen use and sex hormone level was signifi-
cant for women randomized to placebo, that is, baseline T was sig-
nificantly associated with anthropometric changes among hormone
users only in this arm, as was bioavailable T (results not shown).
Discussion
In a secondary analysis of a randomized trial of weight loss interven-
tions in overweight postmenopausal women, we found that elective
estrogen users and nonusers had similar patterns of weight loss with
lifestyle intervention and metformin compared to placebo. Among
estrogen users and nonusers, baseline serum sex steroid levels did not
predict the magnitude of weight loss or reductions in WC in response
to ILS or metformin. This suggests that any effects of exogenous
estrogen were not enacted through actual alteration of serum sex ste-
roid levels. While baseline androgen levels did not predict response to
ILS or metformin, estrogen users randomized to placebo with lower
baseline T and DHEA had greater increases in weight and WC, sug-
gesting that androgen levels could predict women most likely to gain
weight or WC in the absence of intervention.
Reports on whether estrogen therapy can potentiate weight loss
interventions are contradictory. Kuller et al. (7) found that among
approximately 500 postmenopausal women with a mean age of 57
years, reductions in weight and WC in response to lifestyle change
was similar regardless of estrogen use. Our findings were similar.
DPP women who used and did not use estrogen had similar changes
in weight and WC in response to lifestyle change, and the use of
estrogen was not assigned by the DPP trial. It is possible that ran-
domization to estrogen therapy leads to favorable changes in weight
and WC, but that additional beneficial effects of estrogen on weight
loss interventions are minimal. In contrast, Evans et al. (3) found
that women randomized both to estrogen use and lifestyle changes
had the greatest reductions in fat mass, suggesting that the effects of
estrogen therapy and lifestyle change could be additive. Our results
may differ because we examined elective estrogen therapy in mark-
edly overweight dysglycemic women. We also did not find evidence
that actual serum sex steroid levels among estrogen users potentiated
weight loss responses. This finding is consistent with small studies
of oral and transdermal estrogens (4-6), which have reported that
changes in fat mass differed depending upon the route of estrogen
administration; although serum E2 levels were not reported, these
might be assumed to be similar regardless of the route of estrogen
therapy. While these studies differ as to how estrogen therapy may
actually affect weight, these studies and our findings support the
hypothesis that exogenous oral estrogen enacts its effects on weight
through mechanisms other than sex steroid changes.
Although we did not find associations between baseline sex steroid
levels and weight loss among women randomized to interventions,
we did find associations among women randomized to placebo.
Among estrogen users, greater androgen levels (T and DHEA) at
baseline were associated with greater declines in weight and WC.
These results contrast with prior observations that higher androgen
levels are associated with increased lean body mass and fat mass,
particularly among postmenopausal women (13). Other studies have
found that T do not predict weight or WC changes but vice-versa
(12), and that sex steroids and WC associations were of significance
primarily among normal weight women (14). Of note, our results
represent overweight, dysglycemic women over a fairly short period
of time and thus may conflict with reports from healthier popula-
tions of postmenopausal women.
Among women with polycystic ovary syndrome (PCOS), manipula-
tion of steroid levels with flutamide may decrease improvements in
weight apart from a hypocaloric diet (15). However, we did not find
strong evidence that serum sex steroid levels would further potentiate
weight loss interventions, or that additional manipulation of serum sex
steroid levels would further aid weight loss. While the populations of
estrogen users and nonusers were not directly comparable because
estrogen use was elective, both groups of women experienced similar
magnitudes of weight loss and reductions in WC dissociated with
serum sex steroid levels. While some observational studies consis-
tently document strong associations between weight and sex steroid
levels, the nature of the relationship is complex and probably bidirec-
tional (12,16-21). Adipose tissue may manufacture sex steroids, sug-
gested by studies demonstrating that weight reduction in obese women
leads to declines in T (16), increases in WC in the late menopausal
transition precede increases in E2 (12), and hepatic steatosis is associ-
ated with declines in SHBG manufacture (17,18). Conversely, estro-
gen use (19), androgen use (20), and other menopause-related sex hor-
mone changes may influence fat mass and location (12,21).
Strengths of our report include its randomized study of weight loss
interventions which led to significant changes in weight, as well as
measurement of serum sex steroid levels. Limitations include lack
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of more detailed body composition measures that would be allowed
us to examine changes in visceral adiposity and adipose tissue vol-
ume more accurately. Although we used mass spectrometric assays
which may be more sensitive for the low sex steroid levels typically
observed in postmenopausal women, variance was still high at lower
levels and may have biased estimates towards the null. For associa-
tions that were not statistically significant, the point estimates were
close to 0 and the confidence intervals narrow with several excep-
tions, suggesting that these results may have been underpowered:
the association between total estradiol and changes in weight among
nonestrogen users, and the association between DHEA and changes
in WC among estrogen users. Finally, this study was a secondary
analysis of a randomized trial not designed a priori to assess the
interaction between sex steroids upon response to weight loss inter-
ventions in small subsets. Such a study which randomized women to
estrogen therapy as well as to weight loss would be unlikely to be
performed today because of logistics, cost, and ethical concerns.
We conclude that among estrogen users, baseline sex steroid levels
were not associated with intervention response, suggesting that
exogenous estrogen does not potentiate weight loss interventions by
altering serum sex steroid levels. Lower androgen levels may predict
gain in adiposity, although not response to interventions. We also
did not find consistent associations between baseline E2 and inter-
vention responses among women who did not use estrogen. Further
exploration of the interaction between exogenous estrogen and its
impact on metabolic markers should explore other pathways aside
from alterations in sex steroid and SHBG levels.O
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